Zafer Gulbas
- 骨髄移植術のリーディング医師
- 5 優秀 • 23 レビュー
- 49年の経験
- 3315+件の治療実績
- 認定:
- 所在地: トルコ, イスタンブール
アナドル骨髄移植センターの創設者であるグルバシュ教授は、トルコ第1位の血液腫瘍専門医として評価されています。
- 骨髄移植のみを専門とする
- シアトルのフレッド・ハッチンソンをはじめとする主要センターで研鑽を積む
- 2005年より腫瘍内科部長を務める
- Türk Hematoloji Derneği(トルコ血液学会)会員
- 続きを読む
トルコのトップ骨髄移植術医師と価格を比較。こちらで最適なマッチングを見つけてください
ご要望と予算に基づいて最適な医師を厳選いたします
医学的監修者 Fahad Mawlood
医学編集者・データサイエンティストトップ医師
27
トルコ
レビュー
14000+
実際の患者より
トップ各国の骨髄移植術価格を比較
国をタップしてトップ医師と価格を表示
最も人気の範囲
$21K+
$24K+
$27K+
$30K+
$33K+
$36K+
$39K+
$42K+
$27,500 – $34,400
ほとんどの患者がこの範囲内でお支払いです
正確な費用は選択された医師、技術、治療部位、お客様の個別ニーズによって決まります
お客様のケースに正確な見積もりを取得
個別化された治療計画を無料で取得し、最良のオプションを選択してください。コミットメント不要 · サービス料金なし
最初に表示:
アナドル骨髄移植センターの創設者であるグルバシュ教授は、トルコ第1位の血液腫瘍専門医として評価されています。
32名の方が先月見積もりをリクエストしました
Mustafa Solak氏は、骨髄移植を要する複雑な癌症例を専門とし、ハジェテペ大学癌研究所およびMDアンダーソン癌センターにて研鑽を積んでいる。
Education:
2015
Dokuz Eylül University, Medical Faculty, Internal Medicine and Hematology
2010
Dokuz Eylül University, Medical Faculty, Internal Medicine
2005
Hacettepe University, Medical Faculty,
Experience:
2024 –
Istanbul Florence Nightingale Hospital
2017 – 2024
Bağcılar Medipol University Hospital
2017 – 2017
Fırat University
2015 - 2017
Fırat University
2014 - 2015
Mayo Clinic
Publications:
18 Articles Published in International Peer-Reviewed Journals
26 Abstracts and Books Presented at International Scientific Conferences
7 Articles Published in National Peer-Reviewed Journals
51 Abstracts Presented at National Scientific Conferences
Prof. Dr. Ceyhun Bozkurt is a respected Pediatric Hematologist-Oncologist. He is known for his work in childhood blood disorders and cancers. He graduated from Cerrahpaşa Faculty of Medicine. He holds specializations in both Pediatrics and Pediatric Oncology. Since 2019, he has been Professor and Clinical Director at Bahçelievler Medical Park Hospital. He also serves as Vice Director of the Stem Cell Transplant Unit.
Dr. Bozkurt has published over 40 peer-reviewed articles. He is recognized for his work in leukemia, bone marrow transplantation, and stem cell therapy. He is a member of organizations such as SIOP and EBMT. His memberships show his dedication to high standards in clinical care and research.
Experience
Professional Memberships
ドクター ベトゥル・タビル は、小児血液腫瘍学の教授であり、小児骨髄移植における世界的な専門家です。
タビル医師が患者から信頼される理由:
1- SSIテペジック病院 小児腫瘍科(1990年)
2- SSIテペジック病院 小児骨髄移植部門(1992年)
3- ヨーロッパ医学部 小児骨髄移植部門(1998年)
4- 小児研究雑誌 創刊者、2014年;SCI申請は2022年に提出
1. イズミルBUÇ病院 小児骨髄移植部門(2019年)
2. ÜmraniyeEAH 小児骨髄移植部門(2020年)
3. カーヌーニー・スルタン・スレイマンEAH 小児骨髄移植部門(2020年)(チャム・サクラEAH骨髄移植部門へ移管)
Kansoy S.「骨髄・幹細胞移植。小児の健康と疾患」、第1版、EU医学部出版、1999年、イズミル
Kansoy S. 重症型サラセミアIIIにおける骨髄移植。エーゲ・サラセミアデーズ書籍、2000年、イズミル
Kansoy S. トルコにおける小児KIT移植センターの基準。小児急性白血病、アンタルヤ2000年:73-5
Kansoy S. 小児における晩期副作用。Bone Marrow Transplantation Journal of Turkish Clinics 特別号、2003年
Kansoy S. 骨髄・幹細胞移植における幹細胞の応用。小児腫瘍看護学テキスト、イズミル、2005年
Kansoy S. 幹細胞源としての臍帯血。幹細胞特別号、Turkish Clinics、2008年
Kansoy S. リンパ腫における幹細胞移植。一般小児科書籍、Enver Hasanoğlu教授編、2009年
Kansoy S.、Aksoylar S. 小児における骨髄移植。小児科学、2014年および2017年
Kansoy S. 横紋筋肉腫。小児科学、2014年および2017年
Kansoy S. 臨床所見に基づく腫瘍性疾患を有する小児へのアプローチ。小児科学、2014年および2017年
11. Çetingül N.、Kansoy S.、Kantar M. 腫瘍性疾患。小児科学(A. Kura編)、641-672、エーゲ大学出版、イズミル、1999年。(1.05点)
Kansoy S.、M. Kantar. 頭部・顔面・眼の診察。義肢装具士の身体診察と症状に関する情報(A. Kura編)
Kantar M. 腫瘍学における代謝性緊急症の問題。小児期における腫瘍学的緊急症と支持療法(N. Çetingül、S. Kansoy編)、15-24、Meta Basım、イズミル、2003年
トルコにおける臍帯血移植。HEMATOLОГ、2016年
Kansoy S. 小児中枢神経系腫瘍、小児科学、2014年および2017年
小児急性骨髄芽球性白血病およびその治療。小児腫瘍学教科書、Poplack's Turkish版、2020年
小児における造血幹細胞移植の全国的活動、2020年
小児における幹細胞移植の適応、Turkish Clinics — 国際版、2020年
多数の国際学術誌における研究論文・原著論文に加え、インパクトファクターの高い一部の学術誌において国際多施設共同研究にも参加している。
Dr. Toluy Özgümüş has graduated from Istanbul University, Cerrahpaşa Faculty of Medicine in 2008 and completed his internal medicine specialty training at Haydarpaşa Numune Training and Research Hospital between 2009 and 2013. He received his Hematology subspecialty training at Marmara University Hematology Department between 2014-2017; He performed his compulsory service at Kars Harakani State Hospital between 2017-2019. He worked at Sancaktepe Şehit Prof. Dr. Ilhan Varak Training and Research Hospital between 2019-2023.
He is experienced in the field of bleeding and coagulation disorders, especially coagulation disorders (thrombophilia), and has dealt with the diagnosis and treatment of more than 1000 patients. Since he worked in the pandemic hospital of the Anatolian side of Istanbul during the pandemic period, he has extensive experience in the hematological findings of Covid-19 infection and the management of Covid-19 infection in hematological diseases. Hundreds of patient experiences are available in the diagnosis of myeloproliferative diseases such as Polycythemia Vera and Essential Thrombocytosis, in their differentiation from blood cell elevations due to other frequently confused causes, and in their treatment. He has experience in the diagnosis and all treatment processes of rare hematological cancers such as multiple myeloma, acute and chronic leukemias, lymphomas and histiocytosis, as well as bone marrow transplantation.
MEDICAL INTERESTS
Clotting Disorders (Thrombophilia)
Bleeding Disorders
Myeloproliferative Diseases
Anemias (Anemia)
Acute and Chronic Leukemias
lymphomas
Bone marrow transplantation
Prof. Dr. Şebnem İzmir Güner was born in 1970 in Istanbul and took her first steps in her medical career at Istanbul University Faculty of Medicine. Successfully completing her undergraduate and medical education here between 1987-1993, Güner received her internal medicine specialty training at Istanbul University Cerrahpaşa Faculty of Medicine from 1995 to 2000. Deepening her interest in hematology, Prof. Dr. Güner completed her hematology subspecialty training at Cerrahpaşa Faculty of Medicine again between 2003-2006, solidifying her expertise in this field.
Prof. Dr. Güner’s professional journey began as an internal medicine specialist at Istanbul Education and Research Hospital from 2000 to 2003. She established the Hematology Clinic at the same hospital from 2006 to 2010 and served as the responsible physician. Here, she developed innovative approaches in the treatment of patients and made significant contributions to the field of hematology. From 2010 to 2016, she established the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center at Medicalpark Bahçelievler Hospital and served as the responsible physician. During this period, she conducted studies that set national and international standards in the field of hematology.
Between 2016-2018, Prof. Dr. Güner took on similar roles at Şişli Kolon International Hospital, where she was also the founder and responsible physician of the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center. Güner, who became an associate professor in 2017, obtained her professorship title in 2023. Between 2019-2024, she worked at Memorial Şişli Hospital in the Hematology Clinic, Therapeutic Apheresis, and Adult Bone Marrow Transplantation Center.
Prof. Dr. Şebnem İzmir Güner is recognized for her scientific contributions, with over 19 articles published in international peer-reviewed journals. Additionally, she has over 18 articles published in national peer-reviewed journals and 51 presentations at national scientific meetings that have been published in proceedings books. She has also made a name for herself in the academic world with over 18 presentations at meetings and published in proceedings books. Güner, who has held positions on the boards of domestic hematology associations and has active memberships, has crowned her success with more than three awards given at universities and conferences.
Prof. Dr. Şebnem İzmir Güner, who speaks English and German, is also recognized as an educator. In this capacity, she has contributed to the training of young doctors in the field of hematology, providing education to research assistant doctors and students.
Prof. Dr. Şebnem İzmir Güner has established a respected place in the field of hematology with her achievements and scientific contributions throughout her professional life, continuing her career as a physician who inspires her patients and colleagues.
この医師は、小児血液学においてほぼ50年にわたり専念しており、骨髄移植と小児の血液疾患および癌の管理に焦点を当てています。ヨーロッパにおける骨髄移植研究への貢献で認められ、この分野に関連する複雑な手術を専門としています。
この医師は、Children's Cancer Society、European Association for Bone Marrow Transplantation、Turkish and American Society of Hematologyなどの様々な権威ある組織に所属しており、医療コミュニティにおいて重要な存在を確立しています。
1996年に教授の称号を取得し、イスタンブール大学で医学の学位を取得した後、Tsukurov Faculty of Medicineで小児の健康と病気に関する専門的な訓練を修了しました。
Education and Expertise
Ankara University Faculty of Medicine - Medical Education
Gazi University Faculty of Medicine Department of Internal Medicine - Internal Medicine - Specialization
Gazi University Faculty of Medicine Department of Hematology - Hematology - Subspecialty
Duke University Bone Marrow Transplantation Center - Stem Cell Transplantation Training
Fred Hutchinson Cancer Research Center Seattle - Stem Cell Transplant Training
Experience
Duke University-Durham North Carolina Bone marrow transplantation program 2001, cord blood transplant
Fred Hutchinson Cancer Research Center Bone Marrow Transplantation program Seattle 2002, unrelated stem cell transplant
Founder and manager of Gazi University Faculty of Medicine Adult Stem Cell Transplant Unit 2003-2014
Gazi University Faculty of Medicine, Head of Hematology Department 2008-2014
Gazi University Faculty of Health Sciences Dean (founder) 2008-2012
Professional Memberships
Turkish Hematology Association
Bilimsel Yayınları
1. Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.
Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86
2. Deger SM, Erten Y, Suyani E, Aki SZ, Ulusal Okyay G, Pasaoglu OT, Pasaoglu H, Arinsoy T, Turkoz Sucak G. Early Diagnostic Markers for Detection of Acute Kidney Injury in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Exp Clin Transplant. 2017 Apr 14. doi: 10.6002/ect.2016.0161. [Epub ahead of print]
3. Sezer O, Beksac M, Hajek R, Sucak G, Cagirgan S, Linkesch W, Meltem Akay O, Gülbas Z, Nahi H, Plesner T, Snowden JA, Timurağaoğlu A, Dechow T, Lang A, Tuğlular T, Drach J, Armbrecht G, Potamianou A, Couturier C, Olie RA, Feys C, Allietta N, Terpos E. Effects of single-agent bortezomib as post-transplant consolidation therapy on multiple myeloma-related bone disease: a randomized phase II study. Br J Haematol. 2017 Jul;178(1):61-71. doi: 10.1111/bjh.14637. Epub 2017 Apr 6
4. Özkurt ZN, Sucak GT, Akı ŞZ, Yağcı M, Haznedar R.Early Prognostic Value of Monitoring Serum Free Light Chain in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Cancer Invest. 2017 Mar 16;35(3):195-201.
5. Aslan D, Türköz-Sucak G, Percy MJ. Recessive congenital methemoglobinemia in immediate generations.Turk J Pediatr. 2016;58(1):113-115
6. Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N. Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT. Bone Marrow Transplant. 2017 Feb;52(2):209-215. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.
7. Pamukcuoglu M, Acar K, Celik B, Akyurek N, Pepeler MS, Sucak GT. Peripheral and bone marrow CD34+ cell levels on chronic myeloproliferative disease. Hematology. 2017 Mar;22(2):74-80.
8. van Gorkom G, Finel H, Giebel S, Pohlreich D, Shimoni A, Ringhoffer M, Sucak G, Schaap N, Dreger P, Sureda A, Schouten HC. Prospective noninterventional study on peripheral blood stem cell mobilization in patients with relapsed lymphomas. J Clin Apher. 2016 Sep 10. doi: 10.1002/jca.21506. [Epub ahead of print]
9. Necchi A, Miceli R, Bregni M, Bokemeyer C, Berger LA, Oechsle K, Schumacher K, Kanfer E, Bourhis JH, Massard C, Laszlo D, Montoro J, Flechon A, Arpaci F, Secondino S, Wuchter P, Dreger P, Crysandt M, Worel N, Kruger W, Ringhoffer M, Unal A, Nagler A, Campos A, Wahlin A, Michieli M, Sucak G, Donnini I, Schots R, Ifrah N, Badoglio M, Martino M, Raggi D, Giannatempo P, Rosti G, Pedrazzoli P, Lanza F. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party. Bone Marrow Transplant. 2016 Mar;51(3):384-90.
10. Cahu X, Labopin M, Giebel S, Aljurf M, Kyrcz-Krzemien S, Socié G, Eder M, Bonifazi F, Bunjes D, Vigouroux S, Michallet M, Stelljes M, Zuckerman T, Finke J, Passweg J, Yakoub-Agha I, Niederwieser D, Sucak G, Sengeløv H, Polge E, Nagler A, Esteve J, Mohty M; Acute Leukemia Working Party of EBMT. Impact of conditioning with TBI in adult patients with T-cell ALL who receive a myeloablative allogeneic stem cell transplantation: a report from the acute leukemia working party of EBMT. Bone Marrow Transplant. 2016 Mar;51(3):351-7.
11. Marchand T, Lamy T, Finel H, Arcese W, Choquet S, Finke J, Huynh A, Irrera G, Karakasis D, Konopacki J, Lambert J, Michieli M, Schouten HC, Schroyens W, Sucak G, Tischer J, Vandenberghe E, Dreger P. Hematopoietic stem cell transplantation for T-cell large granular lymphocyte leukemia: a retrospective study of the European Society for Blood and Marrow Transplantation. Leukemia. 2016 May;30(5):1201-4
12. Köktürk N, Yıldırım F, Aydoğdu M, Akı ŞZ, Yeğin ZA, Özkurt ZN, Suyanı E, Kıvılcım Oğuzülgen İ, Türköz Sucak G. Is It Possible to Predict Pulmonary Complications and Mortality in Hematopoietic Stem Cell Transplantation Recipients from Pre-Transplantation Exhaled Nitric Oxide Levels? Turk J Haematol. 2016 Mar 5;33(1):34-40.
13. Barğı G, Güçlü MB, Arıbaş Z, Akı ŞZ, Sucak GT. Inspiratory muscle training in allogeneic hematopoietic stem cell transplantation recipients: a randomized controlled trial. Support Care Cancer. 2016 Feb;24(2):647-659
14. Camcıoğlu B, Boşnak-Güçlü M, Karadallı MN, Akı ŞZ, Türköz-Sucak G. The Role of Inspiratory Muscle Training in Sickle Cell Anemia Related Pulmonary Damage due to Recurrent Acute Chest Syndrome Attacks.Case Rep Hematol. 2015;2015:780159. doi: 10.1155/2015/780159. Epub 2015 Apr 28.
15. Fox CP, Boumendil A, Schmitz N, Finel H, Luan JJ, Sucak G, Blaise D, Finke J, Pflüger KH, Veelken H, Gorin NC, Poiré X, Ganser A, Dreger P, Sureda A. High-dose therapy and autologous stem cell transplantation for extra-nodal NK/T lymphoma in Western patients; a study from the European Society for Blood and Marrow Transplantation. Leuk Lymphoma. 2015 Apr 22:1-20.
16. Akı ŞZ, Suyanı E, Cengiz M, Özenirler S, Elbeğ Ş, Paşaoğlu H, Sucak GT. Association between Plasma Endothelin-1, Transforming Growth Factor-β, Fibroblast Growth Factor, and Nitric Oxide Levels and Liver Injury in Hematopoietic Stem Cell Transplantation Recipients with Persistent Iron Overload after Transplantation. Biol Blood Marrow Transplant. 2015 May;21(5):948-953.
17. Beksaç M, Waage A, Bringhen S, Kristinsson SY, Sucak G, Gimsing P, Giulia L, Tuglular TF, Juliusson G, Turesson I, Palumbo A. Does Low Molecular Weight Heparin Influence The Anti-Myeloma Effects Of Thalidomide? A Retrospective Analysis On Data From The GIMEMA, Nordic and Turkish Myeloma Study Groups Acta Haematologica 2015 Mar 24;133(4):372-380
18. Pepeler MS, Acar K, Güzel Tunçcan Ö, Uluoğlu Ö, Kalkancı A, Atalar H, Kılıç K, Türköz Sucak G. A proven case of cutaneous rhizopus infection presenting with severe limb pain very soon after induction treatment in a patient with acute lymphoblastic leukemia. Case Rep Hematol. 2015;2015:285360. doi: 10.1155/2015/285360. Epub 2015 Feb 15.
19. Yegin ZA, Iyidir OT, Demirtaş C, Suyanı E, Yetkin I, Paşaoğlu H, Ilhan C, Sucak GT. The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders. J Endocrinol Invest. 2014 Sep 23. [Epub ahead of print]
20. Tanase A, Schmitz N, Stein H, Boumendil A, Finel H, Castagna L, Blaise D, Milpied N, Sucak G, Sureda A, Thomson K, Vandenberghe E, Vitek A, Dreger P. Allogeneic and Autologous Stem Cell Transplantation for hepatosplenic T cell lymphoma: A retrospective study of the EBMT Lymphoma Working party. Leukemia. 2014 Sep 19. doi: 10.1038/leu.2014.280. [Epub ahead of print]
21. Salihoglu A, Elverdi T, Karadogan I, Paydas S, Ozdemir E, Erdem G, Karadurmus N, Akyol G, Kaynar L, Yegin Z, Sucak G, Ozkocaman V, Topcuoglu P, Ozcan M, Birtas E, Göker H, Başlar Z, Ferhanoglu B. Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey. Ann Hematol. 2014 Sep 18. [Epub ahead of print]
22. Aygencel G, Türkoğlu M, Türköz Sucak G, Benekli M. Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care. 2014 Aug;29(4):618-26.
23. Pamukçuoğlu M, Emmez H, Tunçcan OG, Oner AY, Cırak MY, Senol E, Sucak GT. Brain abscess caused by Nocardia cyriacigeorgica in two patients with multiple myeloma: novel agents, new spectrum of infections. Hematology. 2014 Apr;19(3):158-62.
24. Kadir Acar, Şahika Zeynep Akı, Zübeyde Nur Özkurt, Gülendam Bozdayı, Seyyal Rota, Gülsan Türköz Sucak Factors Associated with Cytomegalovirus Reactivation Following Allogeneic Hematopoietic Stem Cell Transplantation: Human Leukocyte Antigens Might Be Among the Risk Factors Turk J Haematol. 2014 Sep 5;31(3):276-285
25. Abdülkerim Yıldız, Merih Kızıl Çakar, Elif Suyanı, Gülsan Türköz Sucak A Systemic Lupus Erythematosus Patient with Isolated Neutropenia and Diminished Expression of CD55 and CD59 Similar to Paroxysmal Nocturnal Hemoglobinuria doi: 10.4274/Tjh.2013.0318 Pages 323 – 324
26. Suyanı E, Sucak GT, Akyürek N, Sahin S, Baysal NA, Yağcı M, Haznedar R. Tumor-associated macrophages as a prognostic parameter in multiple myeloma. Ann Hematol. 2013 May;92(5):669-77
27. Akyol A, Nazlıel B, Batur Caglayan HZ, Oner Y, Sucak GT. Recurrent Transient Ischemic Attacks in a Patient with POEMS Syndrome. Case Rep Neurol Med 2014:158471
28. Boyacı N, Aygencel G, Turkoglu M, Yegin ZA, Acar K, Sucak GT. The intensive care management process in patients with hematopoietic stem cell transplantation and factors affecting their prognosis. Hematology. 2014 Sep;19(6):338-45
29. Merve Pamukcuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak. Non-Leukemic Granulocytic Sarcoma Presenting with Multiple Skin Nodules and a Retroperitoneal Mass. Turk J Hematol 2013;30:81-82
30. Merve Pamukçuoğlu, Kadir Acar, Nalan Akyürek, Gülsan Türköz Sucak A Rare Case of Acute Leukemia Relapsing with a Granulocytic Sarcoma Causing Ectopic Pregnancy Indian Journal of Hematology and Blood Transfusion April 2013
31. Keser I, Suyani E, Aki SZ, Sucak AG. The positive impact of regular exercise program on stem cell mobilization prior to autologous stem cell transplantation. Transfus Apher Sci. 2013 Jul 6. doi:pii: S1473-0502(13)00205-X. 10.1016/j.transci.2013.06.007. [Epub ahead of print]
32. Buyukasik Y, Acar K, Kelkitli E, Uz B, Serefhanoglu S, Ozdemir E, Pamukcuoglu M, Atay H, Bektas O, Sucak GT, Turgut M, Aksu S, Yagci M, Sayınalp N, Ozcebe OI, Goker H, Haznedaroglu IC. Hyper-CVAD Regimen in Routine Management of Adult Acute Lymphoblastic Leukemia: A Retrospective Multicenter Study. Acta Haematol 2013 Jun 19;130(3):199-205.
33. Yaşar DG, Suyanı E, Özenirler S, Sucak GT. Adefovir is effective to promote development of immunity to donor origin hepatitis B virus in an allogeneic transplant recipient: a case report.Transplant Proc. 2013 Mar;45(2):833-4.
34. Keser I, Suyani E, Yosmaoglu HB, Aki SZ, Sucak AG. Acute physiological responses to physiotherapy applications pre and post autologous stem cell transplantation: an experimental study. Hematology. 2014 Apr;19(3):136-40.
35. Yağcı M, Yegin ZA, Akyürek N, Kayhan H, Ozkurt ZN, Sucak GT, Haznedar R. TCTP/HRF pathway and angiogenesis: a feasible intercourse in chronic lymphocytic leukemia. Leuk Res. 2013 Jun;37(6):665-70.
36. Sucak GT, Cakar MK, Suyanı E, Akı Z, Altındal SE, Acar K. Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey. Hematology. 2013 Sep;18(5):269-76.
37. Türkoğlu M, Erdem GU, Suyanı E, Sancar ME, Yalçın MM, Aygencel G, Akı Z, Sucak G.Acute respiratory distress syndrome in patients with hematological malignancies. Hematology. 2013 May;18(3):123-130.
38. Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A. Paternity wishes in long-term survivors after allogeneic hematopoietic SCT. A study of the late effects working party of the EBMT. Bone Marrow Transplant. 2013 Jun;48(6):878-9.
39. Çakar MK, Suyani E, Sucak GT, Altindal Ş, Aki SZ, Acar K, Yağci M, Rota S, Özenirler S. HBV-related events after allogeneic hematopoetic stem cell transplantatıon in a center from Turkey. Ann Hematol. 2013 Mar;92(3):395-402.
40. Akı ŞZ, Suyanı E, Bildacı Y, Çakar MK, Baysal NA, Sucak GT. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation. Clin Transplant. 2012 Sep-Oct;26(5):E513-2.
41. Akı SZ, Pamukçuoğlu M, Bağrıaçık Ü, Sucak GT. Encephalopathy: an unusual neurologic complication of autologous hematopoietic stem cell transplant in patients with multiple myeloma with renal failure.Leuk Lymphoma. 2013 Apr;54(4):894-6.
42. Rovó A, Aljurf M, Chiodi S, Spinelli S, Salooja N, Sucak G, Hunter A, Kim TS, Socié G, van Lint MT, Passweg JR, Arat M, Badoglio M, Tichelli A; Late Effects Working Party of the EBMT. Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2013 Mar;98(3):339-45.
43. Palumbo A, Waage A, Hulin C, Beksac M, Zweegman S, Gay F, Gimsing P, Leleu X, Wijermans P, Sucak G, Pezzatti S, Juliusson G, Pégourié B, Schaafsma M, Galli M, Turesson I, Kolb B, van der Holt B, Baldi I, Rolke J, Ciccone G, Wetterwald M, Lokhorst H, Boccadoro M, Rodon P, Sonneveld PSafety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica. 2013 Jan;98(1):87-94.
44. Aydoğdu M, Ozyilmaz E, Köktürk N, Yeğin ZA, Özkurt ZN, Aki ZS, Sucak G. Is there any relationship between pulmonary function tests and post-transplant complications of allogeneic hematopoetic stem cell transplantation? Minerva Med. 2012 Jun;103(3):189-98.
45. Suyanı E, Altındal Ş, Akı Ş, Sucak GT. Does fludarabine increase the incidence of sinusoidal obstruction syndrome when combined with Bu/Cy during conditioning? Clin Transplant. 2012 Mar-Apr;26(2):E85-6.
46. Sucak GT, Yaşar DG, Yegin ZA, Ergün MA, Ozkurt ZN, Aki ŞZ, Güntekin S. The prognostic role of hemochromatosis H63D allele in allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2012 Aug;91(8):1281-7.
47. Suyanı E, Sucak GT, Erten Y, Cakar MK, Ulusal G, Yağcı M, Haznedar R. Evaluation of multiple myeloma patients presenting with renal failure in a university hospital in the year 2010. Ren Fail. 2012;34(2):257-62.
48. Sucak GT, Suyanı E, Baysal NA, Altındal Ş, Çakar MK, Akı ŞZ, Yeğin ZA, Şanlıer N.The role of body mass index and other body composition parameters in early post-transplant complications in patients undergoing allogeneic stem cell transplantation with busulfan-cyclophosphamide conditioning. Int J Hematol. 2012 Jan;95(1):95-101.
49. Bağrıaçık EU, Yaman M, Haznedar R, Sucak G, Delibasi T. TSH-induced gene expression involves regulation of self-renewal and differentiation-related genes in human bone marrow-derived mesenchymal stem cells.J Endocrinol. 2012 Feb;212(2):169-78.
50. Elif Suyanı, Zeynep Akı, Zeynep Arzu Yeğin, Gülsan Türköz Sucak. Bortezomib-Associated Severe Orthostatic Hypotension and Hyponatremia Turk J Hematol 2012; 29: 301-302.
51. Zeynep Arzu Yegin, Gülsan Türköz Sucak, Gonca Erbaş, Münci Yağcı ARA-C associated pulmonary toxicity. Turk J Hematol 2011; 28: 81-3.
52. Turkoglu M, Mirza E, Tunçcan OG, Erdem GU, Dizbay M, Yağcı M, Aygencel G, Türköz Sucak G. Acinetobacter baumannii infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. J Crit Care. 2011 Oct; 26(5):460-7.
53. Akı SZ, Paşaoğlu H, Yeğin ZA, Suyanı E, Demirtaş CY, Ozkurt ZN, Yağcı M, Sucak GT. Impact of prohepcidin levels and iron parameters on early post-transplantation toxicities.Hematology. 2011 Sep;16(5):284-90.
54. Yenicesu I, Sucak G, Dilsiz G, Akı SZ, Yeğin ZA. Hematopoietic stem cell transplantation in a very high risk group of patients with the support of granulocyte transfusion. Indian J Hematol Blood Transfus. 2011 Sep;27(3):146-51.
55. Tunçcan ÖG, Aki ŞZ, Akyürek N, Sucak G, Şenol E. Isolated cutaneous aspergillosis in an acute lymphoblastic leukemia patient after allogeneic stem cell transplantation.J Infect Dev Ctries. 2011 May 28;5(5):406-9.
56. Rota S, Fidan K, Bozdayı G, Dalgıç A, Fidan I, Sucak G, Müderris T. [Investigation of BK and JC virus DNA positivities by real-time polymerase chain reaction in the clinical samples of patients with high risk].Mikrobiyol Bul. 2011 Apr;45(2):280-7.
57. Suyanı E, Yağcı M, Sucak GT. Complete remission with a combination of lenalidomide, cyclophosphamide and prednisolone in a patient with incomplete POEMS syndrome. Acta Haematol. 2011;126(4):199-201.
58. Sucak GT, Özkurt ZN, Suyanı E, Yaşar DG, Akdemir ÖÜ, Akı Z, Yeğin ZA, Yağcı M, Kapucu ÖL. Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival. Ann Hematol. 2011 Nov;90(11):1329-36.
59. Ljungman P, de la Camara R, Perez-Bercoff L, Abecasis M, Nieto Campuzano JB, Cannata-Ortiz MJ, Cordonnier C, Einsele H, Gonzalez-Vicent M, Espigado I, Halter J, Martino R, Mohty B, Sucak G, Ullmann AJ, Vázquez L, Ward KN, Engelhard D; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation; Infectious Complications Subcommittee, Spanish Group of Haematopoietic Stem-cell Transplantation. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haematologica. 2011 Aug;96(8):1231-5.
60. Sucak GT, Aki SZ, Yüzbaşioğlu B, Akyürek N, Yağci M, Bağriaçik U, Haznedar R. Prognostic value of bone marrow microvessel density and angiogenic cytokines in patients with multiple myeloma undergoing autologous stem cell transplant. Leuk Lymphoma. 2011 Jul;52(7):1281-9.
61. Yegin ZA, Paşaoğlu H, Aki SZ, Özkurt ZN, Demirtaş C, Yağci M, Acar K, Sucak GT. Pro-oxidative/antioxidative imbalance: a key indicator of adverse outcome in hematopoietic stem cell transplantation.Int J Lab Hematol. 2011 Aug;33(4):414-23.
62. Haznedar R, Akı ŞZ, Akdemir ÖÜ, Özkurt ZN, Çeneli O, Yağcı M, Sucak GT, Unlü M. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma. Eur J Nucl Med Mol Imaging. 2011 Jun;38(6):1046-53.
63. Suyani E, Aki Z, Güzel Ö, Altindal S, Senol E, Sucak G.H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving.Transpl Infect Dis. 2011 Apr;13(2):208-12.
64. Sucak A, Acar K, Celen S, Danisman N, Sucak GT. Outcome of pregnancies in women with thrombophilic disorders.J Obstet Gynaecol. 2010;30(8):847-51.
65. Suyanı E, Sucak GT, Akı ŞZ, Yeğin ZA, Özkurt ZN, Yağcı M. Gemcitabine and vinorelbine combination is effective in both as a salvage and mobilization regimen in relapsed or refractory Hodgkin lymphoma prior to ASCT. Ann Hematol. 2011 Jun;90(6):685-91.
66. Beksaç M, Haznedar R, Firatli-Tuğlular T, Özdogu H, AydoĞdu I, Konuk N, Sucak G, Kaygusuz I, Karakus S, Kaya E, Ali R, Gulbas Z, Ozet G, Goker H, Undar L. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol. 2011 Jan;86(1):16-22.
67. Sucak G, Suyanı E, Özkurt ZN, Yeğin ZA, Aki Z, Yagci M. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance? Hematol Oncol. 2010 Dec;28(4):180-4.
68. Ozyilmaz E, Aydoğdu M, Sucak G, Akı ŞZ, Özkurt ZN, Yeğin ZA, Köktürk N. Risk factors for fungal pulmonary infections in hematopoietic stem cell transplantation recipients: the role of iron overload. Bone Marrow Transplant. 2010 Oct;45(10):1528-33.
69. Tunçcan OG, Yegin ZA, Ozkurt ZN, Erbaş G, Akı SZ, Senol E, Yağcı M, Sucak G. High ferritin levels are associated with hepatosplenic candidiasis in hematopoietic stem cell transplant candidates.Int J Infect Dis. 2010 Sep;14 Suppl 3:e 104-7.
Adult Hematology
Fields of Study and Interests
• Stem cell transplantation (bone marrow transplantation:
autologous/allogeneic)
• Acute leukemias (AML-ALL)
• Chronic leukemias
• Lymphomas (Hodgkin and non-Hodgkin lymphomas)
• Multiple myeloma
• Bone marrow deficiencies (Myelodysplastic syndrome - aplastic anemia etc.)
• Chronic myeloproliferative diseases (polycythemia vera - essential thrombocytosis - primary
myelofibrosis)
• Anemias / Polycythemias (anemia - excess blood)
• Outpatient and inpatient chemotherapies - immunotherapies - targeted therapies
Education
• Faculty of Medicine – Cerrahpaşa Faculty of Medicine 1999-2005
• Internal Medicine Specialist Training – İstanbul Haseki Training and Research Hospital
20062010
• Hematology Subspecialist Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research
Hospital – Hematology and Stem Cell Transplantation Clinic 2013-2017
• Associate Professor İstanbul Ümraniye Training and Research Hospital 2019
Career
• Assistant Doctor Istanbul Haseki Training and Research Hospital-Internal Medicine Clinic
20062010
• Internal Medicine Specialist Istanbul Esenyurt State Hospital 2010-2012
• Internal Medicine Specialist-Military Service Samsun Military Hospital 2012-2013
• Minor Specialization Training Dr. Abdurrahman Yurtaslan Ankara Oncology Training and
Research Hospital – Hematology and Stem Cell Transplantation Clinic 2013-2017
• Hematology Subspecialist Ankara Gülhane Training and Research Hospital, Hematology and
Stem Cell Transplantation Clinic 2017-2018
• Hematology Subspecialist Istanbul Ümraniye Training and Research Hospital/Hematology
2018-2019
• Associate Professor Istanbul Ümraniye Training and Research Hospital/Hematology 2019-2021
• Associate Professor Maltepe University Faculty of Medicine / Hematology 2021-2024
• Associate Professor Istanbul VM Medical Park Pendik Hospital / Hematology and Stem Cell
Transplantation Clinic 2022-2024
アフメット・デミル博士は、急性白血病、ホジキンリンパ腫、さまざまな小児血液疾患の治療に専念してきた20年以上の経験を持つ卓越した小児腫瘍学者およびオンコヘマトロジストです。特に、骨髄移植の実施に精通しています。彼の小児腫瘍学における豊富な研究と出版物は、国際的な認知を得ています。
Serdar Bedii Omay教授は、血液学および骨髄移植に関する65本以上の学術論文を発表しており、この分野において豊富な経験を有しています。
Dr. Hilmi Apak is a respected pediatric hematology-oncology specialist with more than 21 years of experience. He is trained in pediatric oncology. Dr. Apak has led advanced treatments, including bone marrow transplantation, leukemia chemotherapy, and CAR T-cell therapy.
He has published 75 international medical articles, showing his strong contribution to pediatric oncology research. Dr. Apak has worked as assistant editor for the Turkish Pediatrics Archives Periodical. He has also held important academic and leadership positions, such as Head of Pediatric Hematology-Oncology at Istanbul University-Cerrahpaşa.
27名の医師のうち18名をご覧いただきました
海外のクリニックを選ぶことはストレスフルです。800,000名以上の患者をサポートしたBookimedは、お客様の懸念を理解しています。信頼できる医師、最高の価格品質オプション、複雑なケースの解決策を見つける方法を知っています。すべての段階でお客様をご案内いたします。
ヤン・マツィイフスキー
医療コーディネーターチーム責任者
4300+件以上の患者の旅をガイド
Bookimedで3年
Turkeyの278名の患者が今月当社を通じて医師を見つけました
2分のクイズ
目標、予算、スケジュールをお聞かせください
人間のマッチング + AI
アルゴリズムがマッチングを見つけ、コーディネーターが適合性を確認します
オプション準備完了
価格、パッケージ、日程を比較。コーディネーターとチャット
選択肢に迷っていますか?
治療をガイド
医療訓練を受けた専属コーディネーター






| 順位 | 医師 | 経験 | 適合する方 | 特色 | クリニックと所在地 | 診察 |
|---|---|---|---|---|---|---|
| #1 | 49年の経験 | 複雑なリンパ腫症例 | トルコ有数の骨髄移植センターの創設者。フレッド・ハッチンソン癌研究センターおよびMDアンダーソンにて研鑽を積む。最高位の血液腫瘍専門医。 | トルコ | から $280 | |
| #2 | 20年の経験 | 複雑ながん症例 | ハジェテペ癌研究所およびMDアンダーソンで研鑽を積み、移植を要する乳癌・精巣癌・卵巣癌を専門とする。 | トルコ | から $100 | |
| #3 | 36年の経験 | 複雑な血液学的症例 | 日本で研鑽を積んだ分子血液学の専門家。65本以上の学術論文を発表し、トルコの有力大学で教授職を務める。 | トルコ | から $110 |
Istanbul, Ankara, and Antalya host Turkey's highest-rated bone marrow transplant programs, primarily within Joint Commission International (JCI) accredited hospitals. These centers specialized in adult and pediatric stem cell therapy maintain success rates between 80% and 97% for various hematological conditions.
Bookimed Expert Insight: The most comprehensive value is found in Antalya and Izmir, where packages often include 45–60 days of hospitalization. This is vital as Bookimed data shows recovery timelines typically require 90 days of close monitoring post-discharge.
Patient Consensus: Patients frequently highlight the comfort of specialized isolation boxes and the constant presence of multilingual translators. The emotional relief of having staff who go the extra mile significantly aids the recovery process.
Success rates for bone marrow transplantation in Turkey typically range between 80% and 95%. Leading JCI-accredited centers report survival rates up to 97% for adults and 96% for pediatric cases. These outcomes meet or exceed international benchmarks set by top medical institutions in the United States and Europe.
Bookimed Expert Insight: While many clinics highlight high survival rates, the real differentiator is the long-term infrastructure. For instance, Anadolu Medical Center has performed over 3,000 transplants since 2010 with a dedicated center. Look for packages like the one at Medicalpoint International that include 60 days of hospitalization. This extended monitoring period is vital for managing graft-versus-host disease and ensuring long-term success.
Patient Consensus: Patients emphasize that success depends heavily on finding a matched sibling donor before traveling. Many recommend planning for a 3 to 6-month stay to manage recovery and potential complications safely.
Anadolu Medical Center, Memorial Şişli, and Medical Park Antalya are among the top-rated Turkish hospitals for bone marrow transplants. These facilities maintain Joint Commission International accreditation and feature specialized units for both adult and pediatric oncology, high-volume capacity, and success rates reaching 95% for complex cellular therapies.
Bookimed Expert Insight: Anadolu Medical Center stands out because its Bone Marrow Transplant Center was built from the ground up by Professor Zafer Gulbas. His team follows strict Johns Hopkins protocols, which is rare outside the US. This specialized infrastructure allows them to handle 22 transplants simultaneously while maintaining an 81% success rate for autologous procedures.
Patient Consensus: Patients frequently praise the presence of dedicated personal translators and the seamless coordination between airport transfers and hospital admission. Many felt more confident after seeing the high professional level and friendly, supportive environment during their long inpatient stays.
Patients should plan for a minimum stay of 4 to 8 weeks in Turkey for a bone marrow transplant. Autologous procedures typically require 3 to 4 weeks, while allogeneic transplants using donor cells generally necessitate 6 to 8 weeks or longer for essential engraftment monitoring and recovery.
Bookimed Expert Insight: Data shows a major gap between inpatient stays and total recovery packages. While clinical hospitalization averages 45 days at centers like Medical Park Antalya, comprehensive packages often include up to 80 or 110 days of local support. Choosing these extended packages is safer, as they cover the critical outpatient window when complications like infections are most likely to occur.
Patient Consensus: Patients emphasize bringing a dedicated companion because the isolation phase is psychologically taxing. Many suggest booking housing within walking distance of JCI-accredited facilities to simplify daily check-ups after leaving the sterile ward.
Turkish hospitals utilize a hierarchical search protocol to locate unrelated bone marrow donors through the TÜRKÖK national registry and international networks like the World Marrow Donor Association (WMDA). If no family match exists, centers facilitate global donor identification and stem cell procurement within 3 to 8 months.
Bookimed Expert Insight: While a national search takes only 3 days, international cell procurement requires substantial lead time. Anadolu Medical Center offers a specialized 110-day bundled package for unrelated transplants. This rare inclusion covers both the complex global registry search fees and extended post-transplant monitoring under Professor Zafer Gulbas, who has completed over 3,000 procedures.
Patient Consensus: Patients emphasize that while finding an unrelated donor from banks like Germany can take 3 months, the professional coordination and life-saving results justify the wait.
International bone marrow transplant packages in Turkey provide a comprehensive medical ecosystem including pre-transplant diagnostics, chemotherapy conditioning, and sterile hospitalization. These bundles typically integrate logistical support like 24/7 coordination, airport-to-clinic transfers, and long-term accommodation for recovery periods of 30 to 110 days.
Bookimed Expert Insight: While many clinics offer standard 30-day stays, top-tier centers like Anadolu Medical Center or Medical Park Antalya often include up to 110 days of comprehensive clinical coverage. This is a critical differentiator because BMT recovery is rarely linear. Choosing a package with a longer `bundled` hospital stay can prevent unexpected daily ward fees that range from $1,000 to $2,000 if complications arise.
Patient Consensus: Patients frequently highlight the relief of having a dedicated translator and clear communication, which helps navigate the intense emotional stress of a transplant. Many recommend verifying if specialized dietary needs or laundry services are included, as these small daily costs add up during lengthy 3-month recoveries.